Outcomes in Patients Infected with Carbapenem-resistant Acinetobacter Baumannii and Treated with Tigecycline Alone or in Combination Therapy
Overview
Authors
Affiliations
Purpose: Acinetobacter baumannii is a non-fermenting aerobic gram-negative bacteria and one of the important nosocomial pathogens, especially in intensive care units (ICUs). In recent years, multidrug-resistant (MDR) isolates have been an emerging problem, with limited therapeutic options. Tigecycline is a novel antimicrobial, with its in vitro activity against most gram-positive and gram-negative pathogens.
Methods: This is a retrospective study that was conducted in a tertiary care hospital with 550 beds in Ankara, Turkey, from January 2009 to July 2010. Thirty-three patients who had carbapenem-resistant Acinetobacter spp. infections and received tigecycline alone or in combination with other antibiotics for at least 3 days were included.
Results: The median age of the patients was 62 (18-87) years. All of the patients were diagnosed and treated in the ICU. Clinical responses were observed in 23 patients (69.7%). Ten patients (30%) had clinical failure. There was no significant difference between ventilator-associated pneumonia (VAP) and bloodstream infection (BSI) in terms of clinical or microbiological outcome (p > 0.05). The microbiological response rate was 50%. Superinfection was detected in 13 patients (43.3%) and Pseudomonas aeruginosa was the most frequently isolated pathogen. The 30-day overall mortality rate and attributable mortality rates were 57.6 and 24.2%, respectively. The attributable mortality rate was higher in the group in which microbiological eradication was not provided.
Conclusions: Although it is approved by the Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal infections, complicated skin and soft tissue infections, and community-acquired bacterial pneumonia, emerged resistance of Acinetobacter spp. and limited therapeutic options left physicians no choice but to use tigecycline for off-label indications.
Wu D, Chen C, Liu T, Jia Y, Wan Q, Peng J Infect Dis Ther. 2021; 10(1):559-573.
PMID: 33611687 PMC: 7954940. DOI: 10.1007/s40121-021-00411-z.
Yaghoubi S, Zekiy A, Krutova M, Gholami M, Kouhsari E, Sholeh M Eur J Clin Microbiol Infect Dis. 2021; 41(7):1003-1022.
PMID: 33403565 PMC: 7785128. DOI: 10.1007/s10096-020-04121-1.
Wang J, Pan Y, Shen J, Xu Y Ann Clin Microbiol Antimicrob. 2017; 16(1):24.
PMID: 28381268 PMC: 5382384. DOI: 10.1186/s12941-017-0199-8.
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.
Wenzler E, Goff D, Humphries R, Goldstein E Infect Dis Ther. 2017; 6(2):149-172.
PMID: 28260148 PMC: 5446362. DOI: 10.1007/s40121-017-0149-y.
Wu X, Zhu Y, Chen Q, Gong L, Lin J, Lv D Biomed Res Int. 2017; 2016:8395268.
PMID: 28044137 PMC: 5164885. DOI: 10.1155/2016/8395268.